Time Prediction and Cerebellum: Magnetic Transcranial Stimulation (TMS) in Healthy Volunteers

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Mar 5, 2020

Keywords

ClinConnect Summary

This clinical trial, titled "Time Prediction and Cerebellum: Magnetic Transcranial Stimulation (TMS) in Healthy Volunteers," is investigating how a part of the brain called the cerebellum helps us predict time. Researchers will use a technique called magnetic transcranial stimulation (TMS) to target the cerebellum in healthy individuals and measure how this affects their ability to estimate time intervals. The study aims to better understand the role of the cerebellum, which may have implications for conditions like schizophrenia.

To participate, individuals need to be between 18 and 60 years old and must not have any significant neurological or psychiatric disorders, substance abuse issues, or certain medical conditions that would make participation unsafe. Women of childbearing age must have a negative pregnancy test and use effective contraception during the study. Participants can expect to undergo non-invasive brain stimulation and complete tasks that assess their time prediction abilities. This research is currently looking for volunteers, so if you meet the eligibility criteria and are interested, you could contribute to important findings in neuroscience.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant, male or female, between 18 and 60 years old
• • Subject affiliated to a social health insurance scheme (beneficiary or entitled person)
• • Subject who has dated and signed an informed consent form
• • For a woman of childbearing age, negative pregnancy test and effective contraception throughout the study
• Exclusion Criteria:
• • - Participant with substance use disorders (as defined by DSM-V)
• • Participants taking benzodiazepines and related substances (in the period before inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (in the 2 months before inclusion) or hallucinogenic substances (in the period before inclusion, for a duration equivalent to 5 half-lives of the product).
• • Participant with neurological pathology or sequelae
• • Participant with Attention Deficit Hyperactivity Disorder (ADHD)
• • Participant with a borderline personality disorder
• • Participant with disabling sensory impairments, including visual acuity (corrected, if applicable) \< 0.8 (due to use of visual material) (Freiburg Vision Test, Bach 1996)
• • Participant deprived of liberty or subject to the safeguard of justice
• • Participant under guardianship or curatorship
• • Participant in a period of exclusion defined by another clinical study or participant in a study that may impact on research results
• • Pregnant or breastfeeding woman
• • Subject with a contraindication to performing an MRI or TMS: presence of non-removable ferromagnetic body, prosthesis, pacemaker, medication delivered by an implanted pump, vascular clip or stent, heart valve or ventricular lead, certain intracerebral clips, cochlear implants, history of epilepsy, skin pathology at the point of contact with the electrodes.
• • Subject with a history of major neurological or psychiatric illness with current psychotropic medication (i.e., antidepressant, thyroid regulator, antipsychotic, benzodiazepine and related drugs, or hypnotic).